https://www.selleckchem.com/products/skf96365.html
These studies assessed the efficacy and safety of fevipiprant, an oral antagonist of the prostaglandin D (PGD ) receptor (DP ), compared with placebo when added to standard-of-care (SoC) asthma therapy in patients with uncontrolled asthma. ZEAL-1 (NCT03215758) and ZEAL-2 (NCT03226392) are two replicate, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group studies in which fevipiprant 150mg once daily (o.d.) or placebo was added to SoC asthma therapy in patients aged ≥12 years with uncontrolled asthma. Prim
Like
Comment
Share
